Study on Non-Invasive Median Nerve Stimulation for Atrial Fibrillation Post-Ablation
A clinical trial is assessing the efficacy of the CardiaCare RR2 wearable device for reducing atrial arrhythmias after AF ablation.
Phase III
Cardiology / Atrial Fibrillation
Status
Active
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The ongoing clinical trial of the CardiaCare RR2 device represents a potential shift in the management of atrial fibrillation, particularly in the post-ablation setting. Success could lead to new treatment protocols and enhance the competitive landscape for non-invasive therapies in cardiology.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor trial enrollment progress, results from the initial patient cohort, and subsequent data on arrhythmia recurrence rates.
Related companies & assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.